OncologyNurseAdvisor

@ONAcom

Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.

New York, NY

Joined April 2009

408Following

6KFollowers

OncologyNurseAdvisor Retweeted

Tufts Medical Center@TuftsMedicalCtr · Jul 24

Adolescents and young adults face wide-ranging challenges after blood cancer, especially financial ones. A study co-authored by #TuftsMedicine's Susan Parsons, MD, explores tailored support for survivors. Featured in @ONAcom: bit.ly/4lF3RQL #AYAcancer #Survivorship

175

OncologyNurseAdvisor@ONAcom · 3 h

Researchers developed a new risk prediction model for methotrexate-related neurotoxicity in young patients being treated for acute #lymphoblasticLeukemia. Reported in @OncJournal. bit.ly/4fk04Gg #leusm

ONAcom's tweet card. Study identifies the characteristics that predict risk for methotrexate-related neurotoxicity in young patients being treated for ALL.

OncologyNurseAdvisor@ONAcom · 23 h

In a study of more than 6 million #cancersurvivors, about 1 in 12 reported using #cannabis, and nearly half of them said they used cannabis for medical reasons. Published in @JCOOP_ASCO and @CancerTherAdvsr. bit.ly/4f2Lbrr

ONAcom's tweet card. “Amid the growing popularity of cannabis, it is perhaps not surprising that clinicians are increasingly accepting its use among cancer survivors,” the researchers wrote.

OncologyNurseAdvisor@ONAcom · Jul 27

Early oncologic outcomes after RP for very high risk #prostatecancer appear better when patients are staged using PSMA-PET rather than conventional imaging. Presented at #AUA2025. bit.ly/44WRzMq #pcsm

ONAcom's tweet card. Investigators compared early oncologic outcomes by staging modality among men diagnosed with very high-risk prostate cancer.

OncologyNurseAdvisor@ONAcom · Jul 25

Early dynamic variation in the neutrophil-to-lymphocyte ratio during IMRT accurately predicted radiation-induced hepatic toxicity in patients with #hepatocellularCarcinoma. Published in @RareDisease_Adv. bit.ly/4lFXeNY #HCC

ONAcom's tweet card. A higher NLR and rapid NLR shift between weeks 2 and 4 was strongly associated with RILD risk in patients with HCC.

OncologyNurseAdvisor@ONAcom · Jul 24

Sociodemographic disparities affect the uptake of the 2021 United States Preventive Services Task Force’s recommendation to begin #colorectalCancer screening at age 45 years. Published in @DCRjournal and @Gastro_Advisor. bit.ly/4maIvKZ #crcsm

ONAcom's tweet card. Researchers sought to identify social and structural disparities in the uptake of colorectal cancer screening among adults aged 45 years.

OncologyNurseAdvisor@ONAcom · Jul 23

Children with CNS NGGCTs may have better #IQrecovery if they receive proton radiotherapy rather than photon radiotherapy. Presented at @ASCO conference #ASCO2025, covered by @CancerTherAdvsr. bit.ly/3TU7Soi

ONAcom's tweet card. “To our knowledge, this is the first study that demonstrates a clinical advantage of proton therapy for NGGCT,” said David Y. Mak, MD.

OncologyNurseAdvisor@ONAcom · Jul 22

The discharge of pediatric patients after HSCT is a complex and often tenuous process, but a multidisciplinary approach can better prepare patients and their caregivers for the transition from hospital to home. Reported in @NursRep_MDPI. bit.ly/3UoOZKd #hemonc

ONAcom's tweet card. A dedicated discharge team, standardized education, a mandatory 24-hour room-in for caregivers, and appointments with a pharmacist are features that ensure a safe transition from hospital to home for...

OncologyNurseAdvisor@ONAcom · Jul 21

The survivorship experience of young adults, as well as adolescents and children, who have had #bloodcancer varies widely, necessitating carefully tailored interventions to meet their specific needs. Published in @MASCC_JSCC. bit.ly/4lF3RQL #AYACancer

ONAcom's tweet card. Many young adult survivors of childhood hematologic cancer do not have comprehensive survivorship care summaries or believe they need one.

OncologyNurseAdvisor@ONAcom · Jul 20

Topline results were announced from a phase 3 trial evaluating a pembrolizumab-based regimen for the treatment of platinum-resistant recurrent #ovariancancer. From @eMPR and @BusinessWire. bit.ly/3GLIjCM #gyncsm

ONAcom's tweet card. Among patients whose tumors express PD-L1, a statistically significant and clinically meaningful improvement in overall survival was observed.

OncologyNurseAdvisor@ONAcom · Jul 20

Chemotherapy can increase mutation burden and change the cell population structure of normal blood, which contributes to long-term #adverseEffects such as second malignancies and infertility, according to researchers. Reported in @NatureGenet and @CancerTherAdvsr.…

172

OncologyNurseAdvisor@ONAcom · Jul 18

Surgical interval and post-biopsy surgical interval durations do not significantly affect overall prognosis in patients with cutaneous #melanoma. From @DermAdvisor. bit.ly/4lyVYw8 #melsm

ONAcom's tweet card. Researchers examined the affect of surgical interval duration on the prognosis of patients with cutaneous melanoma.

OncologyNurseAdvisor@ONAcom · Jul 17

The @ASCO updated its guidelines on #fertilitypreservation for patients with #cancer. Published in @JCO_ASCO. bit.ly/4nOZxQn

ONAcom's tweet card. ASCO convened a panel of experts to update the clinical guidelines for fertility preservation in men, women, and adolescents with cancer.

OncologyNurseAdvisor@ONAcom · Jul 16

Omitting pelvic lymphadenectomy may be beneficial for patients with early-stage #cervicalcancer undergoing sentinel lymph node biopsy and radical hysterectomy. Presented at the #ASCO2025, covered by @CancerTherAdvsr. bit.ly/3IrvMVt #gyncsm

ONAcom's tweet card. Undergoing sentinel lymph node biopsy and radical hysterectomy without pelvic lymphadenectomy may reduce the risk of retroperitoneal nodal recurrence and cancer-specific death.

OncologyNurseAdvisor@ONAcom · Jul 15

A team-based model employing registered nurses and nursing technicians to provide home-based #palliativecare is a cost-effective model of providing care to patients with advanced #cancer at the end of life. bit.ly/44PvsaK

ONAcom's tweet card. SAD-CP, a home-based palliative care program, was shown to effectively meet the care needs of patients with advanced cancer, particularly in underserved areas.

OncologyNurseAdvisor@ONAcom · Jul 14

Most patients with newly diagnosed #cervicalcancer lack baseline knowledge of palliative care, yet the majority respond favorably to early integration of these services after a brief educational intervention. Published in @gynoncjnls. bit.ly/3TtsinS #gyncsm

ONAcom's tweet card. Responses to an interview study demonstrated that patient education on palliative care led to better understanding of its benefits and greater utilization of these services.

OncologyNurseAdvisor@ONAcom · Jul 13

HER3-DXd demonstrated some activity in a phase 3 trial of patients with previously treated, EGFR-mutant #NSCLC, but a lack of OS benefit prompted the withdrawal of the BLA for the antibody-drug conjugate. From @CancerTherAdvsr bit.ly/4lcoPpO #lcsm

ONAcom's tweet card. HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

298

OncologyNurseAdvisor@ONAcom · Jul 13

The RETREAT score accurately predicted recurrence of #hepatocellularCarcinoma post-liver transplantation. Published in @Gastro_Advisor. bit.ly/3GA32cw #HCC

ONAcom's tweet card. Researchers assess the ability of the Risk Estimation of Tumor REcurrence After Transplant score to predict recurrence of hepatocellular carcinoma in patients who underwent liver transplants as a...

OncologyNurseAdvisor@ONAcom · Jul 11

A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced #melanoma receiving standard immunotherapy. Presented at #ASCO25, covered by @CancerTherAdvsr. bit.ly/3Ixqk3m #melcsm

ONAcom's tweet card. A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

OncologyNurseAdvisor@ONAcom · Jul 10

Retreatment with ICIs following severe #irAEs demonstrated acceptable safety and meaningful antitumor activity, suggesting viability in carefully selected patients. Published in @OncJournal. bit.ly/4liVYA5 #adverseevents